An Open Study Assessing the Safety and Tolerability of U3-1784

NCT02690350 | Terminated Phase 1

• 2 other identifiers: U31784-A-E1012015-002670-20
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 4

Brief Summary

The main objectives of the trial are:

• To evaluate the safety and tolerability of U3-1784 in patients with advanced solid tumours
• To determine the maximum tolerated dose (MTD) and or establish the safety and tolerability of the maximum administered dose (MAD) of U3-1784

Conditions

Advanced Solid Tumors; Hepatocellular Cancer (HCC)

Outcome Measures

Primary Outcomes (2)

• Number of Patients with Adverse Events

  Treatment emergent adverse events (TEAEs) are systematically collected - clinically significant changes in laboratory values are recorded as TEAEs in system organ class: Investigations

  within 1 year

• Number of Patients with Dose-Limiting Toxicities (DLTs)

  from start of treatment until trial termination (within 2 months)

Secondary Outcomes (3)

• Maximum Concentration (Cmax)

  within 2 months

• Time to Cmax (Tmax)

  within 2 months

• Area Under the Curve to the Last Quantifiable Measure (AUClast)[

  within 2 months

Study Arms (3)

Cohort 1 U3-1784 2.5 mg/kg

EXPERIMENTAL

U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated

Drug: U3-1784

Cohort 2 U3-1784 3.75 mg/kg

EXPERIMENTAL

U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated

Drug: U3-1784

Cohort 3 U3-1784 5.6 mg/kg

EXPERIMENTAL

U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated

Drug: U3-1784

Interventions

U3-1784 DRUG

Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated

Also known as: Experimental product

Cohort 1 U3-1784 2.5 mg/kg; Cohort 2 U3-1784 3.75 mg/kg; Cohort 3 U3-1784 5.6 mg/kg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Part 1: Patients with histologically or cytologically confirmed advanced solid tumours refractory to, intolerant of, or not eligible for standard treatment, or who decline standard therapy, or for whom no therapy with curative intent is available
• Part 2: Patients with histologically or cytologically confirmed HCC refractory to, intolerant of, or not eligible for standard treatment, or who decline standard therapy, or for whom no therapy with curative intent is available. If emerging Part 1 data suggest that a particular tumour type or specific tumour histology might be responsive to treatment, then patients with this tumour type or histology will also be included in Part 2 of the study.
• Male or female patients, 18 years of age or older.
• Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to initiation of treatment.
• Males and females of childbearing potential are permitted in the study so long as they consent to avoid getting their partner pregnant or becoming pregnant, respectively, by using a highly effective contraception method, as described below, throughout the study and for up to 90 days after completion. Highly effective methods of contraception include: hormonal methods associated with inhibition of ovulation, intrauterine device; surgical sterilization (including partner's vasectomy) or sexual abstinence, if this is the preferred and usual lifestyle of the subject. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year Eastern Cooperative Oncology Group performance status ≤ 1.
• Life expectancy of greater than 3 months.
• Ability to understand and the willingness to sign a written informed consent form.
• Measurable or evaluable disease as defined by RECIST Version 1.1 in Part 1 of the study (patients included in Part 2 will be required to have measurable disease). The measurable lesion in HCC patients should not be one that has been previously treated by loco-regional therapies (e.g. TACE, RFA) unless this lesion has progressed and there is evidence of new, measurable, enhancement on dynamic imaging.
• Patient has 1 of the following available for pharmacodynamic analyses:
• Archived diagnostic or freshly obtained formalin-fixed paraffin embedded or frozen tumour tissue
• Tumour tissue biopsy collected prior to study drug administration
• Patient has adequate bone marrow, renal, and hepatic function as follows:
• Haemoglobin: ≥ 90 g/L
• Absolute Neutrophil Count: ≥ 1.5 × 109/L
• Platelets: ≥ 100 × 109/L (Part 1); ≥ 75 × 109/L (Part 2)

You may not qualify if:

• Patient has received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy or loco-regional therapy within a period of 21 days prior to Study Day 1 (6 weeks for nitrosureas or mitomycin C). Prior and concurrent use of hormone replacement therapy, use of gonadotropin-releasing hormone modulators for prostate cancer, and use of somatostatin analogues for neuroendocrine tumours are permitted.
• Patient has unresolved clinically significant toxicities from prior anticancer therapy, defined as any National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03; Grade 2 or higher, apart from alopecia.
• Patients with heart failure (New York Heart Association \> Class II) within 6 months prior to study entry; symptomatic coronary artery disease; clinically significant cardiac arrhythmia defined as ≥ Grade 3 to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03; uncontrolled hypertension, myocardial infarction occurring within 6 months prior to study entry.
• Patient has active clinically serious infection defined as ≥ Grade 3 to NCI CTCAE, Version 4.03.
• Patients with clinically significant pericardial effusions, pleural effusions or ascites.
• Patient has had another active malignancy within the past 3 years except for nonmelanoma carcinoma of the skin, cervical carcinoma in situ, and superficial bladder tumours.
• Patient has had major surgery within 4 weeks before enrolment.
• Patient has known hypersensitivity to colestyramine (or any of its excipients) or history of hypersensitivity/allergic reactions attributed to other monoclonal antibodies
• Patients with complete biliary obstruction
• Lactating women
• Concomitant interferon therapy or therapies for active Hepatitis C Virus infection.
• Patient has history of liver transplant.
• Patient has Child-Pugh B-C cirrhotic status based on clinical findings and laboratory results during screening period.

Sponsors & Collaborators

• Daiichi Sankyo: lead

Study Sites (4)

Unknown Facility

Glasgow, Lanarkshire, G12 0YN, United Kingdom

Location

The Royal Marsden Hospital

Sutton, Surrey, United Kingdom

Location

Guy's Hospital

London, United Kingdom

Location

The Christie NHS Foundation Trust

Manchester, United Kingdom

Location

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases

Study Officials

• Alberto Martinez, PhD

  Daiichi Sankyo UK Ltd.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single arm, three cohorts

Study Record Dates

• First Submitted: February 12, 2016
• First Posted: February 24, 2016
• Study Start: February 29, 2016
• Primary Completion: February 28, 2017
• Study Completion: February 28, 2017
• Last Updated: May 16, 2018

Record last verified: 2018-05

Locations

GB (4)